Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EvolusEOLS +1.68%73 3-1 Month Momentum % is -4.71% as of Aug. 17, 2026. GuruFocus rates EOLS with a GF Score™ of 73/100 and a GF Value™ of $13.32 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,026 Drug Manufacturers companies, Evolus ranks better than 52.92% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-17), Evolus's 3-1 Month Momentum % is -4.71%.
The industry rank for Evolus's 3-1 Month Momentum % or its related term are showing as below:
EOLS's 3-1 Month Momentum % is ranked better than 52.92% of 1026
companies
in the Drug Manufacturers industry
Industry Median: -5.74
vs EOLS: -4.71
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Evolus 3-1 Month Momentum % Related Terms
EOLS vs EBS, ELTP, AKBA: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Evolus's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus (EOLS) has a 3-1 Month Momentum % of -4.71% as of Aug. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Evolus and its competitors. According to the industry distribution chart, Evolus ranks #483 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 47.1%.
Is Evolus' 3-1 Month Momentum % too high?
Evolus' current 3-1 Month Momentum % is -4.71%. Based on the distribution chart, Evolus ranks #483 out of 1026 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Evolus has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' 3-1 Month Momentum % compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #483 out of 1026 companies for 3-1 Month Momentum %. This puts Evolus in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Evolus and its competitors. Evolus's current 3-1 Month Momentum % is -4.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.32, compared to a current price of $8.16 — trading 38.8% below its estimated fair value. The current 3-1 Month Momentum % is -4.71%. Evolus' overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Evolus (EOLS), the current 3-1 Month Momentum % is -4.71% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $8.16 is trading 38.8% below its estimated GF Value™ of $13.32.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
3-1 Month Momentum %: -4.71%
GF Value™: $13.32 vs. price of $8.16 (38.8% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
73GF Score
Get the complete analysis for EOLS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
